Background. Sulfadoxine-pyrimethamine (SP) is among the most commonly used antimalarial drugs during pregnancy, yet the pharmacokinetics of SP are unknown in pregnant women. HIV-infected (HIV + ) women require more frequent doses of intermittent preventive therapy with SP than do HIV-uninfected (HIV Ϫ ) women. We investigated whether this reflects their impaired immunity or an HIV-associated alteration in the disposition of SP.
Methods. Seventeen pregnant HIV Ϫ women and 16 pregnant HIV + women received a dose of 1500 mg of sulfadoxine and 75 mg of pyrimethamine. Five HIV Ϫ and 6 HIV + postpartum women returned 2-3 months after delivery for another dose. The pharmacokinetics of sulfadoxine and pyrimethamine were compared between these groups.
Results. HIV status did not affect the area under the curve (AUC 0rϱ ) or the half-lives of sulfadoxine or pyrimethamine in prepartum or postpartum women, although partum status did have a significant affect on sulfadoxine pharmacokinetics. Among prepartum women, the median half-life for sulfadoxine was significantly shorter than that observed in postpartum women (148 vs 256 h; ), and the median AUC 0rϱ was ∼40% P ! .001 lower (22, 816 vs 40,106 mg/mL/h, ). HIV status and partum status did not show any significant influence P ! .001 on pyrimethamine pharmacokinetics.
Conclusion. Pregnancy significantly modifies the disposition of SP, whereas HIV status has little influence on pharmacokinetic parameters in pregnant women.
Sulfadoxine-pyrimethamine (SP) is used in some settings for the treatment of uncomplicated malaria in pregnant women, and it is the only drug currently recommended for intermittent preventive therapy during pregnancy (IPTp). The IPTp regimen consists of at least 2 full treatment doses given in the second trimester and third trimester at intervals at least 1 month [1] . Because of the development of resistance, SP is increasingly being replaced by combination therapy for the treatment of malaria in children and adults. However, among pregnant women, the options for prevention are limited, and SP continues to be widely used as IPTp in pregnancy [2, 3] .
Because physiological functions are altered during pregnancy, the pharmacokinetics of many drugs, including antimalarials, may be different in pregnant women, compared with nonpregnant women [4, 5] . Complex and constantly changing physiological phenomena during the course of pregnancy complicate the situation [6] . Despite its widespread use, the pharmacokinetics of SP has never been described in pregnant women.
It has also been observed that more frequent doses of IPTp are necessary for HIV + women to achieve the same benefits as HIV Ϫ women [7] [8] [9] . The risk of malaria infection in immunosuppressed HIV + persons has been shown to be greater, which partially explains this difference [10] . It is not known whether differences in the pharmacokinetics of SP among HIV + women might contribute to the reduced efficacy of SP as IPTp or be relevant to the case management of malaria in HIV-infected women. Therefore, we examined the pharmacokinetics of a single dose of SP in HIV + and HIV Ϫ women in western Kenya during pregnancy, and again at 2-3 months after delivery, to determine the effects of pregnancy and HIV infection on the disposition of SP.
SUBJECTS, MATERIALS, AND METHODS

Subjects.
The study was conducted at New Nyanza Provincial Hospital in Kisumu from 1999 to early 2000. Primigravid and secundigravid women were included if they had an uncomplicated singleton pregnancy of 16-28 weeks gestation (as assessed by palpation by the midwives in the antenatal clinic), and a hemoglobin level of 18 g/dL. Exclusion criteria included a history of allergies to the study drugs; ingestion of sulfacontaining or 4-aminoquinoline drugs during the previous month; presence of AIDS, as defined by the World Health Organization criteria for adults [11] ; concomitant diseases, such as tuberculosis, or an infection requiring treatment with cotrimoxazole or other sulfa-containing drugs; a mixed malaria infection or a malaria infection due to a species other than Plasmodium falciparum; P. falciparum parasitemia in the presence of documented fever (defined as an axillary temperature у37.5ЊC); and the use of drugs other than folic acid and iron tablets during the period of blood sampling. Clinical malaria (defined as documented fever and parasitemia) was an exclusion criterion, because symptomatic malaria may alter the pharmacokinetics of sulfadoxine [12] , but women with asymptomatic parasitemia could participate, although parasitemia can affect pharmacokinetics as well [13] . Women were asked to act as their own nonpregnant controls during the first 3 months of the postpartum period when almost all were expected to be aparasitemic. To avoid clustering of enrollment of HIV Ϫ women in the beginning of the study, an eligible HIV Ϫ woman was enrolled after the identification and enrollment of a suitable HIV + candidate. This study was conducted before antiretroviral treatment or cotrimoxazole prophylaxis was recommended or available for pregnant women as part of the national policy for the treatment of HIV infection; none of the HIV-infected participants received these treatments. A program for the prevention of mother-to-child transmission of HIV with nevirapine therapy was established in the antenatal clinic at the end of 2000. IPTp with SP was national policy at the time of study, and pregnant women were encouraged to obtain a second dose of SP from the antenatal clinic in the third trimester of their pregnancy.
Ethical review. The institutional review boards of the Kenya Medical Research Institute (Nairobi, Kenya), the Centers for Disease Control and Prevention (Atlanta, Georgia), and the Academic Medical Centre of the University of Amsterdam (Amsterdam, The Netherlands) approved the study protocol. All women who participated gave written informed consent.
Experimental procedure. A 1.5-mL blood sample was obtained by venous puncture immediately prior to the administration of the standard single dose of 3 SP tablets each containing 500 mg of sulfadoxine and 25 mg of pyrimethamine (total dose, 1500 mg of sulfadoxine and 75 mg of pyrimethamine). SP was administered in the same way to all women; clean water was provided to facilitate swallowing, and women were observed to assess whether vomiting occurred. Subsequent blood samples were obtained by venous puncture at 6, 24, 48, 72, 96, 120 (day 5) and 240 (day 10) hours after SP administration. On the first day, women stayed in the study clinic until the second sample was obtained 6 h after administration; on subsequent days, they returned to the clinic so that the sample could be obtained. All blood samples were collected in lithium heparin tubes and stored at Ϫ20ЊC until analysis, which was performed within 12 months of sample collection. The same collection schedule was used for the study repeated during the postpartum period. Levels of sulfadoxine and pyrimethamine in whole blood were determined by high-performance liquid chromatography, performed in accordance with the method described by Green et al. [14] . Interassay variability for sulfadoxine and pyrimethamine was assessed for this study. Standard curve samples for high-performance liquid chromatography analysis consisted of whole blood spiked at the following concentrations: 5, 10, 50, and 100 mg/mL for sulfadoxine and 0.05, 0.1, 0.5, and 1.0 mg/mL for pyrimethamine. Interassay precision (expressed as coefficient of variation [CV]) for sulfadoxine from 18 standard curve runs were 30%, 11%, 6%, and 1%, respectively, for the concentrations stated above, while pyrimethamine showed 77%, 22%, 9%, and 2%, respectively, for the concentrations above. Interassay accuracy (CV) for sulfadoxine was 1%, 15%, 1%, and Ϫ1%, and that for pyrimethamine showed 21%, 16%, 3%, and Ϫ1%, respective to the concentrations stated above.
After participants provided informed consent and received HIV counseling, HIV testing was conducted using 2 rapid test methods: an initial Serostrip HIV-1/2 test (Saliva Diagnostic Systems) and a confirmatory Capillus HIV-1/HIV-2 test (Cambridge Diagnostics) performed on all samples that produced a positive Serostrip result. At all time points when blood samples were obtained for the pharmacokinetic study, blood smears for malaria were performed to assess parasitemia.
Pharmacokinetic analysis. A 1-compartment pharmacokinetic model was used to determine parameters for both sulfadoxine and pyrimethamine. The slope of the least-squares regression analysis of the natural log of drug concentration versus time was used to calculate the elimination constant (k el ) and half-life ) for each subject. The area under (t p Ϫ0.693/k 1/2 el the curve (AUC) from 0 to 240 h (AUC 0r240 ) was calculated using the trapezoidal rule applied to the linear regression curve. The AUC from 0 to infinity hours (AUC 0rϱ ) was determined by combining AUC 0r240 with the area extrapolated from the concentration as determined from the linear regression curve at 240 h divided by the elimination constant of the linear regression curve ( mined the total apparent clearance, Cl/f. Only the patient data sets containing data on blood concentrations from at least the last 3 sampling points (i.e., 96, 120, and 240 h) were use to calculate half-life values. The US Food and Drug Administration recommends that if predose concentration values are greater than 5% of the C max , the subject should be dropped from bioequivalency and/or bioavailability study evaluations [15] . Therefore, the AUCs for such subjects were not determined. The time to peak plasma concentration for sulfadoxine and pyrimethamine occurs from 2 to 6 h after administration [16] . The initial time of sample collection in our study was 6 h after administration, therefore a C max value could not be reliably determined. We estimated the C max to be close to the concentration at 6 h, and we eliminated the AUC values for subjects in whom predose concentrations were greater than 5% of the concentration at 6 h. Statistics. Linear regression methods on log-transformed values for half-lives and AUC 0rϱ were used to compare HIV and partum status while controlling for age, parasite count, and malaria status. Generalized estimating equations were used to account for the correlation of multiple observations taken from the same subject. The Student t test was used on log-transformed values to determine differences between groups.
RESULTS
Participants.
A total of 95 pregnant women were screened, and blood levels of sulfadoxine and pyrimethamine were obtained for 33 participants. Of the 62 women excluded, 14 had hemoglobin levels of !8 g/dL, 39 women were excluded because their HIV status did not fit the sampling schedule, 1 woman was febrile and had a positive blood smear result, and 8 women refused to participate. The median age of the women included was 20 years (range, 15- ) were parasitemic at the start of the study; 1 parasitemic pregnant woman (who was also HIV-infected) had a history of fever in the previous month but her axillary temperature at the time of enrolment was 36.1ЊC. None of the other parasitemic women had a history of fever. For all the women, parasitemia cleared within 3 days after the study treatment with SP. Severe cutaneous reactions were not observed among participants.
Of the 33 women included in the prepartum analysis, 11 participants (6 HIV + and 5 HIV Ϫ women) returned for the postpartum component of the study at 8.6-11.7 weeks after delivery (median, 10 weeks); they all completed the follow-up schedule. One postpartum woman (who was also HIV + ) was parasitemic at the time of enrolment. Among the women who did not participate in the postpartum study, 8 had moved to their rural home or elsewhere, 7 women could not be traced, 5 women refused to participate, and 1 woman died during delivery. There were no significant differences in maternal age, gravidity, or weight (during pregnancy) between women who did and did not participate in the postpartum component of the study; however, women who participated after pregnancy had a higher mean hemoglobin level at enrollment, compared with women who participated only during pregnancy ( , vs. g/dL) ( ). mean ‫ע‬ SD 10.8 ‫ע‬ 1.2 9.9 ‫ע‬ 1.1 P p .04 Sulfadoxine pharmacokinetics. Pharmacokinetic parameters were obtained from whole blood drug concentrations because malaria-infected erythrocytes appear to concentrate sulfadoxine [17] . Linear regression analysis of the control parameters (i.e., age, parasite count, malaria status, and HIV status) did not influence the half-life or AUC 0rϱ values, although partum status did have a significant effect ( ) on P ! .01 sulfadoxine half-life as well as AUC 0rϱ . Because the statistical evidence showed that HIV status had no effect on the pharmacokinetic parameters, the values from the HIV + and HIV Ϫ groups were pooled into prepartum and postpartum sets and compared (table 1) . The median half-life was significantly shorter during pregnancy compared with the postpartum period (148 h vs 256 h; ). Median AUC 0rϱ were ∼40% P ! .0001 lower during pregnancy, compared with the postpartum period (22,816 mg/mL/h vs 40,106 mg/mL/h;
). The rate of P ! .001 clearance was also significantly greater during pregnancy than during the postpartum period (65.9 mL/h vs 36.9 mL/h; P ! ), although pregnancy status showed no significant effect .001 on the volume of distribution in our sample group. Because data on the weight of subjects (kg) were available for the prepartum but not the postpartum women, weight-adjusted V d /f and Cl/f values were calculated only for the prepartum group.
Pyrimethamine pharmacokinetics. Linear regression anal- 
DISCUSSION
In this study, we observed differences in pharmacokinetic parameters between pregnant and nonpregnant women for sulfadoxine, and less so for pyrimethamine. HIV status did not seem to influence the pharmacokinetics of SP during pregnancy.
Previous pharmacokinetic studies of SP were commonly performed on the basis of plasma drug concentrations [12, 13, [18] [19] [20] [21] . Because the mechanism of action of SP occurs within the red blood cell, we consider whole blood concentrations of drug to be more relevant than plasma concentrations. Edstein [17] reported pharmacokinetic parameters in both whole blood and plasma in 7 healthy adult volunteers (6 men and 1 woman), while Barnes et al. [21] has recently reported pharmacokinetic values for subjects (112 years old) with acute falciparum malaria. Because these studies report pharmacokinetic values in whole blood from adults, we used these values for comparison with the pharmacokinetic values determined in our study (table  1) . Because elimination half-lives for sulfadoxine and pyrimethamine are independent of dosing [16] , a direct comparison of elimination half-lives can be made with those determined by Edstein [17] and Barnes et al. [21] (table 1) . Our results show that the half-life values for sulfadoxine in postpartum women (256 h) were similar to those of nonpregnant adults reported by Edstein (227 ‫ע‬ 49 h), however, the half-life during pregnancy was much more rapid (148 h). A lower half-life (possibly in combination with slower absorbance) contributed to the significantly lower AUC 0rϱ observed in pregnancy in our study.
Median pyrimethamine half-life values for prepartum and postpartum women (95 and 102 h, respectively) were within the range of values reported by Edstein [17] Poor absorption of orally administered drugs in pregnant women has been attributed to delayed motility and decreased gastric secretions [6] . Although the volume of distribution is usually increased during pregnancy, we found no significant differences in the V d for sulfadoxine before and after pregnancy. When adjusted for body weight, the value for preg-(V /f )/BW d nant women was 0.24 L/kg. These values were similar to the value reported by Edstein [17] in nonpregnant adults (0.25 ‫ע‬ 0.03 L/kg).
The pregnancy-associated differences in pharmacokinetic parameters that were observed for sulfadoxine were not as apparent for pyrimethamine (table 1) . Greater variability in the pyrimethamine analysis may account for less significant differences in the pharmacokinetic values between the prepartum and postpartum groups.
The effect of pregnancy on the elimination of sulfadoxine, compared with pyrimethamine, may reflect the fact that sulfadoxine is excreted primarily unchanged by the kidneys, whereas 20%-30% of pyrimethamine is excreted unchanged in urine [16] . Drugs that are largely or completely eliminated by the kidney in unchanged form are known to have a shorter elimination half-life during pregnancy [6] .
HIV status has little influence on the pharmacokinetics of SP, suggesting that the observed differences in the efficacy of 2 doses of IPTp with SP result primarily from differences between HIV + and HIV Ϫ women with respect to host factors, such as the effectiveness of the immune response in aiding with the clearance of parasites that survive drug action or possible differences in endogenous folate levels.
In conclusion, the data suggest that pregnancy, at least in the second trimester, adversely alters the pharmacokinetics of sulfadoxine but has little influence on those of pyrimethamine. This is remarkable, given that SP is the antimalarial most commonly used during pregnancy in Africa, but the results are consistent with the recent findings from other pharmacokinetic studies conducted at the Thai-Burmese border with the artemisinins, lumefantrine, atovaquone, and proguanil; all studies show that pregnancy modifies the drugs' disposition, which results in much lower concentrations of the parent drug or metabolites in pregnant women, compared with nonpregnant adults [4, 5] . In many countries where malaria is endemic, antenatal care may be delayed until well into the third trimester. It is likely that the pharmacokinetic differences observed in the second trimester may be even more pronounced in the third trimester, given the differences in physiological conditions. Therefore, second trimester SP kinetics may have more marked implications for IPTp in the third trimester.
Defining the relationship between drug levels and the therapeutic response to SP is complex because of the synergistic interaction between sulfadoxine and pyrimethamine that depends on the drug-resistance genotype of the parasite and corresponding degree of resistance [21, 22] . Our results justify further dose-optimization studies with SP to determine whether higher or more frequent doses are required in pregnant women. We have no evidence that HIV infection had an effect on the disposition of SP in pregnant women.
